Cargando…
Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19
OBJECTIVES: To determine the profile of cytokines in patients with severe COVID-19 who were enrolled in a trial of COVID-19 convalescent plasma (CCP). METHODS: Patients were randomized to receive standard treatment and 3 CCP units or standard treatment alone (CAPSID trial, ClinicalTrials.gov NCT0443...
Autores principales: | Körper, Sixten, Schrezenmeier, Eva Vanessa, Rincon-Arevalo, Hector, Grüner, Beate, Zickler, Daniel, Weiss, Manfred, Wiesmann, Thomas, Zacharowski, Kai, Kalbhenn, Johannes, Bentz, Martin, Dollinger, Matthias M., Paul, Gregor, Lepper, Philipp M., Ernst, Lucas, Wulf, Hinnerk, Zinn, Sebastian, Appl, Thomas, Jahrsdörfer, Bernd, Rojewski, Markus, Lotfi, Ramin, Dörner, Thomas, Jungwirth, Bettina, Seifried, Erhard, Fürst, Daniel, Schrezenmeier, Hubert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582990/ https://www.ncbi.nlm.nih.gov/pubmed/36275695 http://dx.doi.org/10.3389/fimmu.2022.1008438 |
Ejemplares similares
-
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
por: Körper, Sixten, et al.
Publicado: (2022) -
BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents
por: Jahrsdörfer, Bernd, et al.
Publicado: (2021) -
Altered increase in STAT1 expression and phosphorylation in severe COVID‐19
por: Rincon‐Arevalo, Hector, et al.
Publicado: (2021) -
Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies
por: Körper, Sixten, et al.
Publicado: (2021) -
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
por: Desmarets, Maxime, et al.
Publicado: (2023)